Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interstitial Foxp3-positive T cells may predict renal survival in patients with myeroperoxidase anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
Yoshimura J, Fukami K, Koike K, Nagano M, Matsumoto T, Iwatani R, Kusumoto T, Hazama T, Ueda S, Adachi H, Hirai Y, Takasu K, Ohshima K, Yamagishi S, Okuda S. Yoshimura J, et al. Among authors: matsumoto t. Clin Exp Pharmacol Physiol. 2010 Sep;37(9):879-83. doi: 10.1111/j.1440-1681.2010.05412.x. Epub 2010 May 28. Clin Exp Pharmacol Physiol. 2010. PMID: 20528980
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).
Suzuki K, Yokokawa T, Kawaguchi T, Takada S, Tamaki S, Kawasaki Y, Yamaguchi T, Koizumi K, Matsumoto T, Sakata Y, Arakawa Y, Ayuhara H, Hosonaga M, Yamaguchi M, Tsuji D. Suzuki K, et al. Among authors: matsumoto t. Sci Rep. 2024 Nov 16;14(1):28271. doi: 10.1038/s41598-024-79781-6. Sci Rep. 2024. PMID: 39550497 Free PMC article. Clinical Trial.
Evaluation of an ionization chamber characteristics for 222Rn calibration.
Furukawa R, Janik M, Kodaira S, Hashimoto H, Omori Y, Tokonami S, Hosoda M, Shimizu M, Manabe S, Matsumoto T, Shimodan C, Sato Y, Harano H. Furukawa R, et al. Among authors: matsumoto t. Radiat Prot Dosimetry. 2024 Nov 13;200(16-18):1696-1700. doi: 10.1093/rpd/ncae028. Radiat Prot Dosimetry. 2024. PMID: 39540496
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I; PAOLA-1/ENGOT-ov25 investigators. Harter P, et al. Among authors: matsumoto t. Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.10.828. Online ahead of print. Ann Oncol. 2024. PMID: 39528049 Free article.
10,206 results
You have reached the last available page of results. Please see the User Guide for more information.